These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26611266)

  • 1. Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis.
    Tintoré M
    Neurodegener Dis Manag; 2015; 5(6 Suppl):15-7. PubMed ID: 26611266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
    Meuth SG; Vila C; Dechant KL
    Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis.
    Anwar K; Barnes MP
    NeuroRehabilitation; 2009; 24(4):333-40. PubMed ID: 19597271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the management of MS symptoms: recently proposed clinical management algorithms.
    Vermersch P
    Neurodegener Dis Manag; 2015; 5(6 Suppl):23-6. PubMed ID: 26611268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Spasticity in multiple sclerosis].
    Pappalardo A; Patti F; Reggio A; Guglielmino A; Mangiameli S
    Clin Ter; 2004 Apr; 155(4):135-8. PubMed ID: 15354762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.
    Gold R; Oreja-Guevara C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):55-9. PubMed ID: 24289845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spasticity management in multiple sclerosis.
    Hughes C; Howard IM
    Phys Med Rehabil Clin N Am; 2013 Nov; 24(4):593-604. PubMed ID: 24314678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study.
    Arroyo R; Massana M; Vila C
    Int J Neurosci; 2013 Dec; 123(12):850-8. PubMed ID: 23819835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology, assessment and management of multiple sclerosis spasticity: an update.
    Haas J
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):3-8. PubMed ID: 21449853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Country break-out session highlights.
    Fazekas F; Gehring K; Gallo P; Lebrun-Frénay C; Moral E; Myhr KM
    Neurodegener Dis Manag; 2015; 5(6 Suppl):31-7. PubMed ID: 26611270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.
    Farrar JT; Troxel AB; Stott C; Duncombe P; Jensen MP
    Clin Ther; 2008 May; 30(5):974-85. PubMed ID: 18555944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
    Arroyo R; Vila C; Dechant KL
    J Comp Eff Res; 2014 Jul; 3(4):435-44. PubMed ID: 25275238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment and Measurement of Spasticity in MS: State of the Evidence.
    Hugos CL; Cameron MH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(10):79. PubMed ID: 31471769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
    Slof J; Gras A
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):439-41. PubMed ID: 22681512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
    Flachenecker P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis symptom management.
    Boissy AR; Cohen JA
    Expert Rev Neurother; 2007 Sep; 7(9):1213-22. PubMed ID: 17868019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionals.
    Collongues N; Vermersch P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):21-5. PubMed ID: 23369056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
    Collin C; Ehler E; Waberzinek G; Alsindi Z; Davies P; Powell K; Notcutt W; O'Leary C; Ratcliffe S; Nováková I; Zapletalova O; Piková J; Ambler Z
    Neurol Res; 2010 Jun; 32(5):451-9. PubMed ID: 20307378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.